India  

Covid-19 vaccine: Bharat Biotech confirms adverse event during Covaxin phase 1 trial reported within 24 hours

DNA Sunday, 22 November 2020
The adverse event occurred in a 35-year old participant with no co-morbidities, who was part of Phase 1 trials at a site in western India.
0
shares
ShareTweetSavePostSend
 
Video Credit: ANI - Published
News video: 'Covaxin phase-3 trial probably largest clinical trial in India': Principal Investigator

'Covaxin phase-3 trial probably largest clinical trial in India': Principal Investigator 01:36

Phase-3 trial of Covaxin is very crucial, and this is the largest clinically phase-3 trial in India, said Dr. E Venkata Rao, Principal Investigator in the Covaxin human trial to ANI on November 21. He said, "After the success of Phase-1 and 2 of this indigenously developed vaccine by Bharat Biotech....

💡 newsR Knowledge: Other News Mentions

Bharat Biotech Bharat Biotech Indian biotechnology company and vaccine manufacturer

Jharkhand Police: ₹ 35 lakh as fine from masses violating Covid norms  | Oneindia News [Video]

Jharkhand Police: ₹ 35 lakh as fine from masses violating Covid norms | Oneindia News

Thousands of people including Covid patients evacuated because of Cyclone Tauktae from Gujarat and Maharashtra; Bharat Biotech said that the company manufactured Covaxin is effective against the aggressively virulent strains of Covid detected in India and in the UK; Delhi police said that an Aam Admi Party party member is the brain behind the posters that appeared around parts of Delhi a few days ago; Delhi Chief Minister Arvind Kejriwal today said the Delhi government will take all necessary steps and precautions to check cases of black fungus or mucormycosis in the city; Jharkhand Police has collected over ₹ 35 lakh as fine from people for not wearing masks in public places. #CycloneTauktae #Covaxin #AAP #BlackFungus #JharkhandPolice

Credit: Oneindia    Duration: 03:39Published

Covaxin effectively neutralises all key emerging variants, says study published in Oxford journal

Indigenous Covid-19 vaccine Covaxin has been able to neutralise all key emerging variants, including the double mutant B.1.617 and B.1.1.7, which was first..
IndiaTimes

COVID-19 COVID-19 Disease caused by severe acute respiratory syndrome coronavirus 2

Zee 24 Ghanta editor Anjan Bandyopadhyay dies in Kolkata due to COVID-19

Family sources said that Anjan Bandyopadhyay had tested positive for COVID-19 in mid-April following which he was hospitalised.
DNA

Study: Covid deaths have affected 82% of elderly with anxiety

Loneliness and a deepening sense of uncertainty has hit the senior citizens like never before during the second wave of Covid-19 pandemic, according to the..
IndiaTimes

Tauktae now ‘very severe’ cyclone, set to rip into Gujarat at 185kmph

Covid-bruised Gujarat braced for a battering by the strongest cyclone to hit its coast since 1998 as Tauktae, which cut a swathe through the western coastal belt..
IndiaTimes

‘PM Cares helped triple number of ventilators’

Ventilators allocated to states and Union Territories under PM Cares and the health ministry have more than tripled availability of the critical care machines in..
IndiaTimes

You Might Like


Related videos from verified sources

Watch: PM Modi reviews development of Covid vaccine candidate ZyCoV-D [Video]

Watch: PM Modi reviews development of Covid vaccine candidate ZyCoV-D

Prime Minister Narendra Modi began his three-city visit to review coronavirus vaccine development work by going to pharma major Zydus Cadila's manufacturing facility near Ahmedabad. Wearing a PPE kit,..

Credit: HT Digital Content     Duration: 02:10Published
COVID-19: Phase-3 trial of Covaxin begins at Ahmedabad's Sola Civil Hospital [Video]

COVID-19: Phase-3 trial of Covaxin begins at Ahmedabad's Sola Civil Hospital

Phase-3 trial of Covaxin began at Sola Civil Hospital in Gujarat's Ahmedabad. Volunteers are coming at the hospital for the test. "Volunteers who've been vaccinated have yet not complained of any..

Credit: ANI     Duration: 01:53Published
Watch: Haryana Health Minister Anil Vij administered trial dose of Covaxin [Video]

Watch: Haryana Health Minister Anil Vij administered trial dose of Covaxin

Haryana Health Minister Anil Vij was administered a trial dose of Covaxin on Friday. 67-year old Vij was administered the trial dose at the Civil Hospital at Ambala Cantt. On Wednesday, Vij had said..

Credit: HT Digital Content     Duration: 01:43Published